Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Creo Medical ( (GB:CREO) ) has shared an announcement.
Creo Medical Group PLC announced that its Non-Executive Chairman, Kevin T. Crofton, has acquired 701,750 ordinary shares of the company at an average price of 15.75 pence per share. This transaction, conducted on the London Stock Exchange, increases Crofton’s total shareholding to 5,447,416 shares, representing 1.32% of voting rights. The acquisition signifies confidence in the company’s strategic direction and could positively influence stakeholder perceptions and market positioning.
More about Creo Medical
Creo Medical is a medical device company focused on developing and commercializing minimally invasive electrosurgical devices. The company aims to enhance patient outcomes through its CROMA technology, powered by Kamaptive, which integrates multi-modal energy sources for surgical procedures. This technology offers clinicians flexibility, precision, and control, potentially transforming surgery and endoscopy by providing safer, less-invasive, and cost-efficient options.
Average Trading Volume: 1,753,611
Technical Sentiment Signal: Sell
Current Market Cap: £61.87M
For detailed information about CREO stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue